Chemodex

2-Fluoro-2-deoxy-D-glucose

CHF 115.00
In stock
CDX-F0076-M02525 mgCHF 115.00
CDX-F0076-M100100 mgCHF 299.00
More Information
Product Details
Synonyms 2-Deoxy-2-fluoro-D-glucose; FDG; 2-FG; Fluorodeoxyglucose
Product Type Chemical
Properties
Formula

C6H11FO5

MW 182.15
CAS 29702-43-0
Purity Chemicals ≥97% (NMR)
Appearance White to yellow powder.
Solubility Soluble in DMF (30mg/ml), DMSO (30mg/ml) or water (10mg/ml).
Identity Determined by 1H-NMR.
Declaration Manufactured by Chemodex.
Other Product Data

Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.

InChi Key ZCXUVYAZINUVJD-IVMDWMLBSA-N
Smiles O[C@H]1C(F)C(O)[C@H](O)[C@@H](CO)O1
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice Protect from light and moisture.
Use/Stability Stable for at least 2 years after receipt when stored at -20°C.
Documents
MSDS Inquire
Product Specification Sheet
Datasheet Download PDF
Description

2-Fluoro-2-deoxy-D-glucose [FDG] is a glucose analog that inhibits cellular glycosylation. It is the natural isotope-form of 18F-FDG that can be taken up by cells but does not undergo metabolic glycolysis. FDG uptake is closely related to the expression of the glucose transporter (GLUT) in malignant tumours. FDG is also a substrate of hexokinase isozymes and an inhibitor of cellular glycosylation. FDG is taken up by high-glucose-using cells such as brain, brown adipocytes, kidney and cancer cells, where phosphorylation prevents the glucose from being released again from the cell, once it has been absorbed. The 2-hydroxyl group (–OH) in normal glucose is needed for further glycolysis (metabolism of glucose by splitting it), but FDG is missing this 2-hydroxyl and cannot be further metabolized in cells. FDG is used in positron emission tomography (PET) as contrast agent and is the most widely used PET marker. FDG-PET can be used for diagnosis, staging, and monitoring treatment of cancers, particularly in Hodgkin's disease, non-Hodgkin lymphoma, colorectal cancer, breast cancer, melanoma, and lung cancer. FDG has also anticancer and chemosensitizing activity.

Product References

(1) H. Minn, et al.; Res. Exp. Med. 191, 27 (1991) | (2) Y. Kanazawa, et al.; J. Neurochem. 66, 2113 (1996) | (3) T.J. Lampidis, et al.; Cancer Chemother. Pharmacol. 58, 725 (2006) | (4) Y. Liu, et al.; Prostate Cancer Prostatic Dis. 9, 230 (2006) | (5) Y. Pina, et al.; Invest. Ophthalmol. Vis. Sci. 53, 996 (2012) | (6) A. Fantagare & A. Svatos; Front. Plant Sci. 7, 483 (2016) | (7) S. Niccoli, et al.; PLosOne 12, e0187584 (2017) | (8) N. Hasnain, et al.; J. Pak. Med. Assoc. 70, 2291 (2020)

© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.